![]() |
|
|
Vol. 62, Issue 1, 110-118, July 2002
Department of Pharmacology, The University of Michigan Medical
School, Ann Arbor, Michigan
It is established that
NG-amino-L-arginine (NAA) is a
metabolism-based inactivator of all three major nitric-oxide
synthase (NOS) isoforms. The mechanism by which this
inactivation occurs, however, is not well understood. In the current
study, we discovered that inactivation of the neuronal isoform of NOS
(nNOS) by NAA in vitro results in covalent alteration of the heme
prosthetic group, in part, to products that contain an intact porphyrin
ring and are either dissociable from or irreversibly bound to the
protein. The alteration of the heme is concomitant with the loss of
nNOS activity. Studies with nNOS containing a 14C-labeled
prosthetic heme moiety indicate that the major dissociable product and
the irreversibly bound heme adduct account for 21 and 28%,
respectively, of the heme that is altered. Mass spectral analysis of
the major dissociable product gave a molecular ion of
m/z 775.3 that is consistent with the mass of an adduct
of heme and NAA minus a hydrazine group. Peptide mapping of the
irreversibly bound heme adduct indicates that the heme is bound to a
residue in the oxygenase domain of nNOS. We show for the first time
that metabolism-based inactivation of nNOS occurs in vivo as highly similar heme products are formed. Because inactivation and alteration may trigger ubiquitination and proteasomal degradation of nNOS, NAA may
be a useful biochemical tool for the study of these basic regulatory processes.
This article has been cited by other articles:
![]() |
W. B. Pratt, Y. Morishima, and Y. Osawa The Hsp90 Chaperone Machinery Regulates Signaling by Modulating Ligand Binding Clefts J. Biol. Chem., August 22, 2008; 283(34): 22885 - 22889. [Full Text] [PDF] |
||||
![]() |
A. Y. Dunbar, Y. Kamada, G. J. Jenkins, E. R. Lowe, S. S. Billecke, and Y. Osawa Ubiquitination and Degradation of Neuronal Nitric-Oxide Synthase in Vitro: Dimer Stabilization Protects the Enzyme from Proteolysis Mol. Pharmacol., October 1, 2004; 66(4): 964 - 969. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Demady, E. R. Lowe, A. C. Everett, S. S. Billecke, Y. Kamada, A. Y. Dunbar, and Y. Osawa METABOLISM-BASED INACTIVATION OF NEURONAL NITRIC-OXIDE SYNTHASE BY COMPONENTS OF CIGARETTE AND CIGARETTE SMOKE Drug Metab. Dispos., July 1, 2003; 31(7): 932 - 937. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Osawa, E. R. Lowe, A. C. Everett, A. Y. Dunbar, and S. S. Billecke Proteolytic Degradation of Nitric Oxide Synthase: Effect of Inhibitors and Role of hsp90-Based Chaperones J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 493 - 497. [Abstract] [Full Text] [PDF] |
||||